Skip to main content

Table 2 Comparison of subjective and objective parameters at baseline vs. at 4, 12, and 24 weeks

From: Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia

 

Baseline

Week 4

Week 12

Week 24

Total IPSS

17.0 (14.0–21.0)

13.0 (10.3–16.0)***

13.5 (8.8–16.0)***

9.5 (8.8–13.3)***

Q1. Incomplete emptying

2.0 (1.0–3.0)

2.0 (1.0–2.0)*

1.0 (1.0–3.0)

1.0 (0.8–2.3)*

Q2. Daytime frequency

3 (2.3–3.0)

3.0 (2.0–3.0)**

2.0 (2.0–3.0)**

1.0 (1.0–2.0)***

Q3. Intermittency

2.5 (2.0–3.0)

2.0 (1.0–3.0)

1.0 (1.0–3.0)**

1.0 (1.0–2.0)**

Q4. Urgency

2.0 (1.0–3.0)

1.0 (1.0–2.0)**

2.0 (1.0–2.0)*

1.0 (1.0–2.0)*

Q5. Weak stream

3.0 (2.0–4.0)

2.5 (2.0–3.0)**

2.0 (1.8–3.0)***

2.0 (2.0–2.3)**

Q6. Straining

2.0 (1.0–3.0)

1.0 (1.0–2.0)

1.0 (1.0–2.0)*

1.0 (1.0–1.0)*

Q7. Nocturia

2.0 (2.0–3.0)

2.0 (1.0–2.0)**

2.0 (1.0–2.3)**

2.0 (1.0–2.0)*

Voiding symptom subscore

9.0 (8.0–12.0)

8.0 (4.0–10.0)*

7.0 (5.0–9.3)***

5.5 (4.8–7.5)***

Storage symptom subscore

7.0 (6.0–9.0)

5.0 (4.0–8.8)***

5.5 (4.0–7.0)**

4.0 (3.0–5.3)**

QOL score

4.0 (3.0–5.0)

3.0 (2.0–3.8)**

3.0 (2.0–3.0)***

2.0 (2.0–2.5)**

Total OABSS

5.0 (3.0–6.0)

4.5 (3.0–6.0)

4.0 (2.3–6.0)*

3.0 (3.0–4.0)*

SHIM

7.5 (2.3–12.0)

10.5 (4.3–13.5)

10.5 (5.0–16.3)*

11.0 (4.5–16.5)*

NPi

0.4 (0.3–0.5)

0.4 (0.4–0.4)

0.4 (0.3–0.4)

0.3 (0.3–0.4)

Night-time maximum voided volume (mL)

240.0 (157.5–275.0)

270.0 (230.0–300.0)*

300.0 (250.0–340.0)*

290.0 (240.0–310.0)*

Maximum flow rate (mL/s)

9.4 (7.3–13.8)

10.0 (6.3–13.9)

10.6 (5.8–14.0)

11.0 (6.4–12.7)

Residual urine volume (mL)

47.0 (21.0–81.5)

31.5 (17.0–76.8)

44.0 (20.0–93.5)

38.0 (0.0–76.8)

  1. Data are presented as the median (interquartile range)
  2. IPSS, international prostate symptom score; voiding symptom subscore (Q1 + Q3 + Q5 + Q6); storage symptom subscore (Q2 + Q4 + Q7); QOL, quality of life; OABSS, overactive bladder symptom score; SHIM, sexual health inventory for men; NPi, nocturnal polyuria index
  3. *P < 0.05; **P < 0.01; ***P < 0.001, compared with baseline